πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 71 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11117970

Human antibodies to PD-L1

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10982215

Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of us

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10889813

Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10858432

Antibodies specific to glycosylated PD-1 and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10836827

Antibodies specific to glycosylated PD-L1 and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822414

Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using an

Sutro Biopharma, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10786552

Il-2RΞ²-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 anti

Nektar Therapeutics Β· Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10744116

Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

The Regents of the University of California Β· Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10745704

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10737113

Human antibodies to PD-1

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10736976

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10683347

Treatment of cancer using anti-TGF-Ξ² and anti-PD-1 antibodies

The Regents of the University of California Β· Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10618967

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10457725

Methods of treating skin cancer by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10167334

Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

The Regents of the University of California Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10010587

IL-2RΞ²-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 anti

Nektar Therapeutics Β· Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9987500

Human antibodies to PD-1

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938345

Human antibodies to PD-L1

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932593

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9765147

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9422562

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8507663

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted